Impact News +++ Galp lifts FY guidance as refining margins drive strong Q2 (Investing.com) +++ GALP ENERGIA Aktie -5,85%

TEVA Aktie

>TEVA Aktienkurs

27 EUR -0.4% (TradegateBSX)

Ask: 27.3 EUR / 500 Stück

Bid: 26.8 EUR / 500 Stück

Tagesumsatz: 6722 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TEVA Aktie über LYNX handeln

Intraday

1 Jahr

>TEVA Performance

1 Woche: -4,6%

1 Monat: -9,6%

3 Monate: +4,2%

6 Monate: 0%

1 Jahr: +94,3%

laufendes Jahr: +1,1%

>TEVA Aktie

Profil:

Teva Pharmaceutical Industries Ltd. ADR represents shares of an Israeli-based global pharmaceutical company focused on developing, manufacturing, and marketing medicines across multiple therapeutic areas. Teva is widely recognized for its large portf..
>Volltext..

Insiderhandel:

>TEVA Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>TEVA Anleihen

>TEVA Peer Group

Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Onkologie/ Krebs- Behandlung

>TEVA Chart & Kurs - NYSE

>TEVA News

26.07.26 - 21:12	Teva′s Turnaround Is Working. Here′s the 1 Thing That Could Send It Soaring Another 50%. (Fool)
	The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline....

26.07.26 - 16:24	Wall Street Thinks Teva Can Soar Over 60%. Here′s Why Analysts Are Right. (Fool)
	The stock has a 100% buy rating from polled analysts, with some eye-catching price targets....

19.07.26 - 14:36	Teva stock′s downward trend continues (Globes)
	Despite the recent losses, analyst Ori Hershkovitz sees a 31% upside in the Israeli pharmaceutical company’s share price....

16.07.26 - 18:30	Teva on track to snap seven straight sessions of losses (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.07.26 - 00:48	Teva lawsuit over generics of Lilly′s Forteo brought back by appeals court (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.07.26 - 22:06	Rechtsstreit um Forteo: Berufungsgericht lässt Klage von Teva Pharm gegen Eli Lilly wieder zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.07.26 - 12:12	Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar (PBR)
	Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it obtains regulatory approval. The arrangement covers markets, including The post Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar appeared first on Pharmaceutical Business review....

09.07.26 - 18:48	Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? (Fool)
	Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?...

09.07.26 - 15:42	Teva And Samsung Bioepis Enter Commercialization Agreement For OPUVIZ In Canada (AFX)
	PETAH TIKVA (dpa-AFX) - On Thursday, Teva Pharmaceutical Industries Ltd. (TEVA) and Samsung Bioepis Co., Ltd., a unit of Samsung Epis Holdings Co. Ltd. (0126Z0.KS), announced that they have entere......

09.07.26 - 15:30	Teva, Polpharma ink licensing pact for biosimilar targeting Roche’s Ocrevus (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

09.07.26 - 15:18	Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar (AFX)
	PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global lice......

09.07.26 - 14:33

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis (GlobeNewswire EN)

TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics' proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics' proven biosimilar development expertise with Teva's commercial footprint and capabilities....

07.07.26 - 17:00	Teva reports positive skin treatment drug results (Globes)
	The Israeli company reported in the study that patients showed improvements in skin pigmentation with vitiligo....

07.07.26 - 14:01	Teva startet Phase-2b-Studie mit Vitiligo-Antikörper nach positiven Daten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.07.26 - 19:48	Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? (Fool)
	Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion....

29.06.26 - 15:15	Pharma-Unternehmen Teva setzt auf Wasserstoff-LKW von Hylane (SolarServer)
	Der Ratiopharm-Produzent Teva setzt in der Logistik künftig auf einen Brennstoffzellen-LKW von Iveco. Vermieterin des Wasserstoff-Fahrzeuges ist die Kölner Hylane. Foto: Hylane...

25.06.26 - 09:06	Israeli companies shutting down Turkish operations (Globes)
	Sanitaryware company Hamat left Turkey last week but some including Teva, ICL and Netafim continue to operate there despite the political tensions between the countries....

23.06.26 - 17:31	Teva′s Shift Beyond Generics Puts Focus on Branded Drug Growth (Zacks)
	TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix....

23.06.26 - 00:01	Insiderhandel: EVP, Global Operations verkauft Aktien von Teva Pharma Industries im Wert von 321547 USD (Insiderkauf)
	Shields, Matthew - Vorstand - Tag der Transaktion: 2026-06-18...

19.06.26 - 16:45	Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome (Zacks)
	TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Aus einem Weisen wird man nicht klug. - Elazar Benyoetz

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram